Lumida
/MDGL
⌘K
Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

MDGL
$534.49USD+0.26%+1.37 today

MARKET CAP

12.3B

P/E (TTM)

FWD P/E

DAY RANGE

$531 – $547

52W RANGE

$394
$615

AI Summary

Stalk
StalkMedium

MDGL has formed a Stage 2 accumulation base, consolidating in a tight range above rising EMAs. Medium-term bias is bullish, favoring long entries on breakouts or high-conviction pullbacks. Short-term execution is on hold as price is extended above EMAs and near overbought conditions, warranting patience. Long-term trend remains intact above the 200 DMA.

  • Q2 revenue rose 71% YoY to $364.3M, driven by ResDifera demand.
  • ResDifera prescribed to over 49,000 patients, signaling robust market penetration.
  • Q2 net loss of $57.9M reflects SG&A expenses of $289.4M.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2019FY 2024FY 2025TREND
Sales, Adj.$0$180.1M$958.4M
YoY %+432.1%
P / Sales36.4x13.6x
EV / Sales37.5x14.1x
Gross Profit, Adj.$0$180.1M$958.4M
YoY %+432.1%
Margin %100.0%100.0%
EV / Gross Profit37.5x14.1x
EBITDA, Adj.$-94.9M$-496.8M$-298.6M
YoY %-133.7%-30.7%+39.9%
Margin %-275.8%-31.2%
EV / EBITDA-14.6x-13.6x-45.3x
EBIT$-95.0M$-497.9M$-300.1M
YoY %-133.4%-30.8%+39.7%
Margin %-276.4%-31.3%
EV / EBIT-14.5x-13.6x-45.1x
Net Income$-83.9M$-465.9M$-288.3M
YoY %-155.9%-24.7%+38.1%
Net Margin-258.6%-30.1%
EPS (GAAP)-$5.45-$21.90-$12.85
YoY %-145.5%-9.6%+41.3%